Susan Galbraith, AstraZeneca EVP of oncology R&D (Rachel Kiki for Endpoints News)
April 5, 2023 07:29 AM EDTUpdated 11:35 AM
R&D

As­traZeneca's Lyn­parza-Imfinzi com­bo clears PhI­II tri­al in ovar­i­an can­cer

Katherine Lewin

News Reporter

As­traZeneca tout­ed pos­i­tive da­ta for its Lyn­parza-Imfinzi block­buster com­bo to­day with a high-lev­el analy­sis from its DUO-O Phase III tri­al, in new­ly di­ag­nosed pa­tients with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times